Prognostic models in alcohol-related liver disease and alcohol-related hepatitis

IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Best Practice & Research Clinical Gastroenterology Pub Date : 2023-12-01 DOI:10.1016/j.bpg.2023.101867
Jessica Ann Musto, Michael Ronan Lucey
{"title":"Prognostic models in alcohol-related liver disease and alcohol-related hepatitis","authors":"Jessica Ann Musto,&nbsp;Michael Ronan Lucey","doi":"10.1016/j.bpg.2023.101867","DOIUrl":null,"url":null,"abstract":"<div><p><span>Alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH) are dynamic disorders whose prognosis can be challenging to determine. A number of prognostic models have been developed to determine likelihood of death, when to refer for liver transplant (LT) and the role for </span>glucocorticoids<span>. Often these models were created with a specific application in mind but were found to have additional applications with further study. Those prognostic models that have stood the test of time are easy to use, have clear interpretations and employ objective parameters. These parameters most often include total bilirubin, INR and creatinine among other data points. Ideally, these models could be utilized at all phases of disease but in most, it is important for clinicians to consider drinking history and how it might alter the determined scores. Herein we provide a brief review of prognostic models in ALD and AH and provide practical tips and considerations to successfully make use of these tools in a clinical setting.</span></p></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521691823000501","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH) are dynamic disorders whose prognosis can be challenging to determine. A number of prognostic models have been developed to determine likelihood of death, when to refer for liver transplant (LT) and the role for glucocorticoids. Often these models were created with a specific application in mind but were found to have additional applications with further study. Those prognostic models that have stood the test of time are easy to use, have clear interpretations and employ objective parameters. These parameters most often include total bilirubin, INR and creatinine among other data points. Ideally, these models could be utilized at all phases of disease but in most, it is important for clinicians to consider drinking history and how it might alter the determined scores. Herein we provide a brief review of prognostic models in ALD and AH and provide practical tips and considerations to successfully make use of these tools in a clinical setting.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
酒精相关肝病和酒精相关肝炎的预后模型
酒精相关性肝病(ALD)和酒精相关性肝炎(AH)是动态疾病,其预后很难确定。已经开发了许多预后模型来确定死亡的可能性,何时进行肝移植(LT)以及糖皮质激素的作用。通常,这些模型是为特定的应用程序而创建的,但通过进一步研究发现它们具有其他应用程序。那些经受住时间考验的预测模型易于使用,有明确的解释,并采用客观参数。这些参数通常包括总胆红素、INR和肌酐等数据点。理想情况下,这些模型可以用于疾病的所有阶段,但在大多数情况下,临床医生考虑饮酒史及其如何改变确定的分数是很重要的。在此,我们简要回顾ALD和AH的预后模型,并提供实用的技巧和注意事项,以成功地在临床环境中使用这些工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.50
自引率
0.00%
发文量
23
审稿时长
69 days
期刊介绍: Each topic-based issue of Best Practice & Research Clinical Gastroenterology will provide a comprehensive review of current clinical practice and thinking within the specialty of gastroenterology.
期刊最新文献
The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy Gut microbiota in colorectal cancer: From pathogenesis to clinic Editorial Board Table of Contents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1